Showing 1 to 1 of 1 results
english.elpais.com
🌐 85% Global Worthiness


Losartan Shows Promise for Butterfly Skin, but Funding for Clinical Trial Remains a Challenge
Losartan, a hypertension drug, shows promise in treating epidermolysis bullosa (butterfly skin) lesions, but a €5-10 million clinical trial is needed for EMA approval, highlighting challenges in repurposing drugs for rare diseases.
Losartan Shows Promise for Butterfly Skin, but Funding for Clinical Trial Remains a Challenge
Losartan, a hypertension drug, shows promise in treating epidermolysis bullosa (butterfly skin) lesions, but a €5-10 million clinical trial is needed for EMA approval, highlighting challenges in repurposing drugs for rare diseases.
Progress
36% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results